Allergic bronchopulmonary aspergillosis (ABPA) is a complex hypersensitivity reaction
to Aspergillus fumigatus, mainly characterized by severe asthma symptoms, hyper eosinophilia in blood, lung
and airways, elevated serum IgE levels, bronchiectasis, bronchial mucoid impaction
and lung fibrosis [
[1]
]. As recently remarked, oral corticosteroids (OCS) and antifungal therapy currently
represent the gold standard treatment [
[2]
]; however, despite their proven efficacy, they may cause severe side effects, especially
in the case of prolonged therapy.- Agarwal R.
- Muthu V.
- Sehgal I.S.
- Dhooria S.
- Prasad K.T.
- Garg M.
- et al.
A randomised trial of prednisolone versus prednisolone and itraconazole in acute-stage
allergic bronchopulmonary aspergillosis complicating asthma.
Eur Respir J. 2021; (Online ahead of print)2101787https://doi.org/10.1183/13993003.01787-2021
Key words
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of Internal MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Allergic bronchopulmonary aspergillosis.Indian J Med Res. 2020; 151: 529https://doi.org/10.4103/ijmr.IJMR_1187_19
- A randomised trial of prednisolone versus prednisolone and itraconazole in acute-stage allergic bronchopulmonary aspergillosis complicating asthma.Eur Respir J. 2021; (Online ahead of print)2101787https://doi.org/10.1183/13993003.01787-2021
- Global burden of allergic bronchopulmonary aspergillosis with asthma and its complication chronic pulmonary aspergillosis in adults.Med Mycol. 2013; 51: 361-370https://doi.org/10.3109/13693786.2012.738312
- Biologics for the treatment of allergic conditions: eosinophil disorders.Immunol Allergy Clin North Am. 2020; 40: 649-665https://doi.org/10.1016/j.iac.2020.07.001
- Mepolizumab for allergic bronchopulmonary aspergillosis: report of 20 cases from the Belgian Severe Asthma Registry and review of the literature.J Allergy Clin Immunol. 2020; 8 (2412–3.e2)https://doi.org/10.1016/j.jaip.2020.03.023
- Effect of α1 antitrypsin deficiency on lung volume decline in severe asthmatic patients undergoing biologic therapy.J Allergy Clin Immunol Pract. 2021; 9: 1414-1416https://doi.org/10.1016/j.jaip.2020.12.061
- ABPA complicating asthma ISHAM working group. Allergic bronchopulmonary aspergillosis: review of literature and proposal of new diagnostic and classification criteria.Clin Exp Allergy. 2013; 43: 850-873https://doi.org/10.1111/cea.12141
- The role of IgE in upper and lower airway disease: more than just allergy!.Clin Rev Allergy Immunol. 2021; https://doi.org/10.1007/s12016-021-08901-1
- Type 2 immunity in asthma.World Allergy Organ J. 2018; 11https://doi.org/10.1186/s40413-018-0192-5
- Monitoring treatment response in chronic pulmonary aspergillosis: role of clinical, spirometric and immunological markers.Clin Microbiol Infect. 2019; 25 (1157.e1-1157.e7.)https://doi.org/10.1016/j.cmi.2019.01.007
Article info
Publication history
Published online: January 06, 2022
Accepted:
December 29,
2021
Received in revised form:
December 26,
2021
Received:
September 16,
2021
Identification
Copyright
© 2022 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.
